Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription 11.08.2025 1 Acta Cytol 2 AJR Am J Roentgenol 2 Am J Clin Oncol 1 Ann Oncol 14 Ann Surg Oncol 3 Anticancer Res 3 BMC Cancer 1 Br J Cancer 3 Breast Cancer 1 Breast Cancer (Dove Med Press) 1 Breast Cancer Res 9 Breast Cancer Res Treat 1 Cancer Res 8 Clin Breast Cancer 1 Clin Exp Metastasis 1 Eur J Cancer 1 Eur J Surg Oncol 2 Eur Radiol 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 4 J Biol Chem 1 J Clin Invest 1 J Clin Oncol 1 J Nucl Med 2 Lancet 1 N Engl J Med 1 Nature 3 NPJ Breast Cancer 1 Oncology 6 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiol Artif Intell 3 Radiology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Cytol

1. NIKAS IP, Yang SH, Lim S, Lee H, et al
   The Prognostic Significance of Ki-67 Expression in Breast Cancers Developing Malignant Effusions.
   Acta Cytol. 2025;69:352-360.
   PubMed         Abstract available
   
   

   
   AJR Am J Roentgenol

2. THOMAS M, Andrews-Tang D
   Beyond the AJR: Supplemental Breast Cancer Screening in Women with Dense Breasts in the United Kingdom-BRAID Study Shows Impressive Results, But at What Cost?
   AJR Am J Roentgenol. 2025 Aug 6. doi: 10.2214/AJR.25.33647.
   PubMed        
   
   
3. NOORILY AR, Heller SL, Regen-Tuero HC, Li X, et al
   Novel Wash-In Characteristics of Background Parenchymal Enhancement on Ultrafast Dynamic Contrast-Enhanced Breast MRI.
   AJR Am J Roentgenol. 2025 Apr 23. doi: 10.2214/AJR.24.32624.
   PubMed         Abstract available
   
   

   
   Am J Clin Oncol

4. EL FAKIH A, Loap P, Cabel L, Allali S, et al
   Real-world Safety of Concurrent Pembrolizumab and Radiotherapy in Triple-negative Breast Cancer.
   Am J Clin Oncol. 2025 Aug 8. doi: 10.1097/COC.0000000000001236.
   PubMed         Abstract available
   
   
5. JAIN D, Upreti K, Tak TK, Date SS, et al
   Predicting and Optimizing Synergistic Drug Combinations for Breast Cancer Treatment Using Machine Learning.
   Am J Clin Oncol. 2025 Aug 6. doi: 10.1097/COC.0000000000001244.
   PubMed         Abstract available
   
   

   
   Ann Oncol

6. GRAESER M, Gluz O, Zu Eulenburg C, Kuemmel S, et al
   Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials.
   Ann Oncol. 2025 Aug 4:S0923-7534(25)00913-5. doi: 10.1016/j.annonc.2025.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

7. OU X, Liu Z, Liu C, Wang K, et al
   Surgical and Oncologic Outcomes of Tumescence and Sharp Dissection Versus Electrocautery Dissection in Minimal-Access Nipple-Sparing Mastectomy with Immediate Prosthesis Breast Reconstruction: A Real-World Retrospective Cohort Study.
   Ann Surg Oncol. 2025;32:6660-6670.
   PubMed         Abstract available
   
   
8. LEVY J, Wagner BD, Roberts A, Shammas RL, et al
   The Impact of Travel Distance on Patient Outcomes after Breast Reconstruction.
   Ann Surg Oncol. 2025;32:6629-6639.
   PubMed         Abstract available
   
   
9. VARMAN PM, Conner A, Bennett WC, Taft D, et al
   Impact of Second Opinions on Time to Treatment of Breast Cancer.
   Ann Surg Oncol. 2025 Aug 2. doi: 10.1245/s10434-025-17934.
   PubMed         Abstract available
   
   
10. LUBARSKY M, Hernandez AE, Borowsky PA, Thompson C, et al
    ASO Visual Abstract: A Comprehensive Analysis of Unmet Social Needs in Patients with Breast Cancer Treated at an Academic Cancer Center and Sister Safety-Net Hospital.
    Ann Surg Oncol. 2025 Aug 3. doi: 10.1245/s10434-025-17720.
    PubMed        
    
    
11. LEE EG, Lee DE, Jung SY, Han JH, et al
    ASO Visual Abstract: Clinical Application of Multimodal Sentinel Lymph Node Mapping Method in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: A Final Analysis.
    Ann Surg Oncol. 2025 Aug 4. doi: 10.1245/s10434-025-17961.
    PubMed        
    
    
12. CHEN JC, Handley D, Elsaid MI, Carson WE, et al
    Omitting Sentinel Lymph Node Biopsy in Small Hormone Receptor-Positive Breast Cancer: Does Race Matter?
    Ann Surg Oncol. 2025 Aug 4. doi: 10.1245/s10434-025-18038.
    PubMed        
    
    
13. ALTUNDAG K
    Reassessing Predictors of Nodal Pathologic Complete Response in Breast Cancer: Methodological Strengths and Data Gaps in the National Cancer Database.
    Ann Surg Oncol. 2025 Aug 4. doi: 10.1245/s10434-025-18055.
    PubMed        
    
    
14. LUBARSKY M, Hernandez AE, Borowsky PA, Thompson C, et al
    A Comprehensive Analysis of Unmet Social Needs in Breast Cancer Patients Treated at an Academic Cancer Center and Sister Safety-Net Hospital.
    Ann Surg Oncol. 2025 Aug 4. doi: 10.1245/s10434-025-17609.
    PubMed         Abstract available
    
    
15. FUJINO S, Yamashita K, Okamoto R, Shibaki S, et al
    Exploring the Role of CDO1 in Breast Cancer: Insights into Tumor Biology and Therapeutic Potential.
    Ann Surg Oncol. 2025 Aug 5. doi: 10.1245/s10434-025-17944.
    PubMed         Abstract available
    
    
16. BRENNAN MA, Plichta JK, Rozenblit M, Flanagan MR, et al
    Surgeon Attitudes on the Management of de novo Oligometastatic Breast Cancer.
    Ann Surg Oncol. 2025 Aug 6. doi: 10.1245/s10434-025-17912.
    PubMed        
    
    
17. CHEN JH, Warneke CL, Middleton L, Singh P, et al
    ASO Visual Abstract: Complication Rates Are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy.
    Ann Surg Oncol. 2025 Aug 7. doi: 10.1245/s10434-025-18064.
    PubMed        
    
    
18. MANN GB
    ASBrS Keynote Address: Reimagining Stage 1 Breast Cancer-Evolution of Breast Cancer Management over the Last 120 Years.
    Ann Surg Oncol. 2025 Aug 7. doi: 10.1245/s10434-025-17849.
    PubMed        
    
    
19. EDWARDS M, Elder K, Rose A, Tan E, et al
    ASO Visual Abstract: Survival Benefits and Less Intensive Treatment for Women Diagnosed with Early-Stage Breast Cancer While Participating in Population-Based Screening.
    Ann Surg Oncol. 2025 Aug 7. doi: 10.1245/s10434-025-18069.
    PubMed        
    
    
20. STARI OL, Torok C, Gorog PO, Markus B, et al
    ASO Author Reflections: The Completion May Lead to Conservation: Partial and Complete Intraoperative Ultrasound Enhanced Breast-Conserving Surgery for Invasive Breast Cancer.
    Ann Surg Oncol. 2025 Aug 8. doi: 10.1245/s10434-025-18009.
    PubMed        
    
    

    
    Anticancer Res

21. FUJIYOSHI K, Sugihara R, Miyamoto N, Watanabe Y, et al
    Comparison of Comprehensive Genomic Profiling Testing "Ion Torrent Genexus Sequencer" With FoundationOne.
    Anticancer Res. 2025;45:3479-3486.
    PubMed         Abstract available
    
    
22. IIDA K, Iwabuchi E, Miki Y, Hasegawa K, et al
    Detection of Somatostatin Receptors by Ligand Derivative Staining in Breast Tumors.
    Anticancer Res. 2025;45:3221-3230.
    PubMed         Abstract available
    
    
23. PARK SH, Yoon DH, Kim J, Park SI, et al
    Deletion of the POLR2J4 Gene in Breast Cancer Cells Promotes Bone Metastatic Tumor Growth.
    Anticancer Res. 2025;45:3263-3273.
    PubMed         Abstract available
    
    

    
    BMC Cancer

24. AL-MASRI M, Aljalabneh B, AlMasri R, Alayyan O, et al
    Comparative survival analysis of HER2-positive Pregnancy-Associated Breast Cancer (PABC) and non-Pregnancy-Associated breast Cancer (non-PABC) cohorts: a matched control study.
    BMC Cancer. 2025;25:1252.
    PubMed         Abstract available
    
    
25. TAFESE AM, Fentie MT, Seifu BL, Asnake AA, et al
    Breast cancer survival rates and determinants in Ethiopia: a systematic review and meta-analysis of longitudinal studies.
    BMC Cancer. 2025;25:1263.
    PubMed         Abstract available
    
    
26. SAROOSH R, Ahmad N, Israr B, Nazir A, et al
    Association of diabetes mellitus and breast cancer in adult men and women: a cross-sectional survey.
    BMC Cancer. 2025;25:1276.
    PubMed         Abstract available
    
    

    
    Br J Cancer

27. JING Y, Wu Y, Hu Q, Wu W, et al
    Remodelling hypoxic TNBC microenvironment restores antitumor efficacy of Vgamma9Vdelta2 T cell therapy.
    Br J Cancer. 2025;133:365-380.
    PubMed         Abstract available
    
    

    
    Breast Cancer

28. MATSUNUMA R, Nakagaki S, Nakatani E, Kikuchi M, et al
    Impact of modified dexamethasone administration sequence on infusion reaction incidence in HER2-positive breast cancer: a randomized multicenter trial.
    Breast Cancer. 2025 Aug 2. doi: 10.1007/s12282-025-01752.
    PubMed         Abstract available
    
    
29. KITAGAWA H, Fukuzawa K, Tanaka M
    Regional disparities in breast cancer healthcare in Japan: REAL-BC study.
    Breast Cancer. 2025 Aug 2. doi: 10.1007/s12282-025-01739.
    PubMed         Abstract available
    
    
30. CHARALAMPOPOULOU A, Filippatos C, Malandrakis P, Zagouri F, et al
    A systematic review of the efficacy of cancer vaccines in advanced breast cancer.
    Breast Cancer. 2025 Aug 5. doi: 10.1007/s12282-025-01751.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Dove Med Press)

31. CARVALHO GS, Gomes DM, Bretas GO, Teixeira VBG, et al
    Late Breast Cancer Recurrence Prediction: The Role of CTS5 and Progesterone Receptor Status.
    Breast Cancer (Dove Med Press). 2025;17:683-691.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

32. LOPEZ-MIRANDA E, Perez-Garcia JM, Gion M, Ribelles N, et al
    Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial.
    Breast Cancer Res. 2025;27:141.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

33. VACHARANUKRAUH P, Miller KJ, Alif SM, Grace F, et al
    Pharmacological interventions for anthracycline-induced cardiotoxicity in breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Breast Cancer Res Treat. 2025 Aug 5. doi: 10.1007/s10549-025-07791.
    PubMed         Abstract available
    
    
34. LLOYD K, Newman LA, Glass C, Ogayo ER, et al
    Assessing racial disparities in disease outcomes of patients with high-risk, triple-negative breast cancer and residual disease after neoadjuvant therapy: a post-hoc analysis of the ECOG-ACRIN 1131 clinical trial.
    Breast Cancer Res Treat. 2025 Aug 4. doi: 10.1007/s10549-025-07798.
    PubMed         Abstract available
    
    
35. IWASE T, Sridhar N, Kai M, Dong W, et al
    Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study.
    Breast Cancer Res Treat. 2025 Aug 2. doi: 10.1007/s10549-025-07795.
    PubMed         Abstract available
    
    
36. ZHAN H, Chan NNN, Khaimova R, Aung TN, et al
    Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.
    Breast Cancer Res Treat. 2025;213:273-279.
    PubMed         Abstract available
    
    
37. MIDDLETON LP, Perkins GH, Whitman GJ, Mouabbi JA, et al
    Immediate and ipsilateral recurrence rates and treatment recommendations for patients with pleomorphic and florid lobular carcinoma in situ.
    Breast Cancer Res Treat. 2025;213:225-235.
    PubMed         Abstract available
    
    
38. BELTRAN-BLESS AA, de Lima Machada I, Clemons L, Pond GR, et al
    Do regularly scheduled visits result in earlier detection of curable breast cancer recurrences?
    Breast Cancer Res Treat. 2025 Aug 5. doi: 10.1007/s10549-025-07793.
    PubMed         Abstract available
    
    
39. WANG MJ, Rastegar A, Kung TA
    Readability analysis of breast cancer resources shared on X-implications for patient education and the potential of AI.
    Breast Cancer Res Treat. 2025 Aug 6. doi: 10.1007/s10549-025-07799.
    PubMed         Abstract available
    
    
40. OIKONOMIDOU O, Beresford MJ, Galve-Calvo E, Woeckel A, et al
    Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2- advanced breast cancer in Europe.
    Breast Cancer Res Treat. 2025 Aug 6. doi: 10.1007/s10549-025-07707.
    PubMed         Abstract available
    
    
41. BEHLAM I, Sudershan A, Priya I, Sudershan S, et al
    Association between ESR1 polymorphisms (XbaI & PvuII) and breast cancer risk: a comprehensive meta-analysis of case-control studies.
    Breast Cancer Res Treat. 2025 Aug 8. doi: 10.1007/s10549-025-07800.
    PubMed         Abstract available
    
    

    
    Cancer Res

42. QI Z, He L, Xu Z, Luo X, et al
    PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m6A Methylation to Stabilize PARP1 mRNA.
    Cancer Res. 2025 Aug 7. doi: 10.1158/0008-5472.CAN-24-4751.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

43. VAZ REIS R, Pinto P, Peleteiro B, Luis Fougo J, et al
    Evaluation of Residual Axillary Lymph Node Metastases After Neoadjuvant Treatment in Breast Cancer.
    Clin Breast Cancer. 2025 Jul 12:S1526-8209(25)00207.
    PubMed         Abstract available
    
    
44. MAHMOUD MA, Fayanju OM, McCarthy AM, Zeballos Torrez CR, et al
    Exploring Imaging Biomarkers to Improve Equity in Supplemental and High-Risk Breast Cancer Screening Between Black and White Women: A Perspective on Background Parenchymal Enhancement and Breast Density.
    Clin Breast Cancer. 2025 Jul 11:S1526-8209(25)00204.
    PubMed         Abstract available
    
    
45. AMADEN GH, Hyland KA, Winger JG, Kelleher SA, et al
    Examining the Interrelationships of Lymphedema with Pain, Physical Function, and Demographic and Medical Variables in Women with Breast Cancer and Pain.
    Clin Breast Cancer. 2025 Jul 9:S1526-8209(25)00203.
    PubMed         Abstract available
    
    
46. LI S, Mou J, Huang G, Zeng X, et al
    Breast Cancer in Working-Age Men: A Population-Based Investigation of Global, Regional, and National Disease Burdens Between 1990 and 2021.
    Clin Breast Cancer. 2025 Jul 16:S1526-8209(25)00208.
    PubMed         Abstract available
    
    
47. GONCALVES AC, Reinert T, da Cruz HMF, Costa E Silva M, et al
    Real-World Treatment Patterns and Outcomes in Hormone Receptor Positive HER2 Negative Early-Stage Breast Cancer in a Private Community Oncology Practice of Brazil.
    Clin Breast Cancer. 2025 Jul 11:S1526-8209(25)00205.
    PubMed         Abstract available
    
    
48. LI Y, Li D, Tao X, Ye Y, et al
    Integrated Prognostic Model for Young Breast Cancer Patients: Insights from SEER, METABRIC, and TCGA Databases.
    Clin Breast Cancer. 2025 Jul 21:S1526-8209(25)00210.
    PubMed         Abstract available
    
    
49. OKABE A, Ho WLJ, Tao ML, Ye JC, et al
    Physician and Software Assessed Cosmetic Outcomes Following Whole Breast or Partial Breast Radiation Therapy for Breast Cancer.
    Clin Breast Cancer. 2025 Jul 8:S1526-8209(25)00201.
    PubMed         Abstract available
    
    
50. LIU J, Sun J, Fang H, Luo J, et al
    Farnesyltransferase Inhibitor (R115777) Targets CENPF to Inhibit Breast Cancer Bone Metastasis by Regulating the PI3k/AKT/mTOR/PTHrP Pathway.
    Clin Breast Cancer. 2025 Jul 10:S1526-8209(25)00185.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

51. ZHANG W, Rahman S, Wu AML, Isanogle K, et al
    A CSF-1R inhibitor both prevents and treats triple-negative breast cancer brain metastases in hematogenous preclinical models.
    Clin Exp Metastasis. 2025;42:45.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

52. ZUO H, Vaihenberg E, Singh A, Bal G, et al
    Impact of early discontinuation of adjuvant endocrine therapy on survival in breast cancer: A target trial emulation.
    Eur J Cancer. 2025;227:115665.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

53. DALTON L, Rakha E
    Transcriptomic classifiers do not reliably predict lymph node involvement in breast Cancer: Insights from three large cohorts.
    Eur J Surg Oncol. 2025;51:110354.
    PubMed         Abstract available
    
    

    
    Eur Radiol

54. BOLAN PJ, Rahbar H, Partridge SC
    Can we cut the contrast? DWI shows similar value to standard MRI for assessing treatment response in breast cancer.
    Eur Radiol. 2025 Aug 7. doi: 10.1007/s00330-025-11912.
    PubMed        
    
    
55. SUBELACK J, Morant R, Blum M, Grawingholt A, et al
    Retrospective evaluation of interval breast cancer screening mammograms by radiologists and AI.
    Eur Radiol. 2025 Aug 4. doi: 10.1007/s00330-025-11833.
    PubMed         Abstract available
    
    

    
    Int J Cancer

56. JOHN EM, Koo J, Keegan TH, Gomez SL, et al
    Overall and central adiposity and risk of contralateral breast cancer: The California Breast Cancer Survivorship Consortium.
    Int J Cancer. 2025 Aug 7. doi: 10.1002/ijc.70073.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

57. LEVIN D, Shekel E, Rosenfeld H, Grinfeld G, et al
    Beyond Technology: The Impact of Personal Physics Consultation on Patient Anxiety in Breast Cancer Radiotherapy.
    Int J Radiat Oncol Biol Phys. 2025 Aug 4:S0360-3016(25)06044.
    PubMed         Abstract available
    
    
58. GOMA C, Molla M, Oses G, Sanfeliu E, et al
    Preoperative Radiotherapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results from the YOUNGSTER Trial.
    Int J Radiat Oncol Biol Phys. 2025 Aug 1:S0360-3016(25)06042.
    PubMed         Abstract available
    
    

    
    J Biol Chem

59. EL-SAWY L, Rubin JR, Broses L, Patsalis C, et al
    The molecular mechanism of ambrosin induced cytotoxicity of human breast cancer and bladder cancer cells.
    J Biol Chem. 2025 Aug 1:110531. doi: 10.1016/j.jbc.2025.110531.
    PubMed         Abstract available
    
    
60. KHARAT SS, Mishra AP, Sengodan SK, Dierman D, et al
    5hmC enhances PARP trapping and restores PARP inhibitor sensitivity in chemoresistant BRCA1/2-deficient cells.
    J Biol Chem. 2025;301:110393.
    PubMed         Abstract available
    
    
61. SHI S, Li X, Alderman C, Wick L, et al
    Cryo-EM structures reveal the PP2A-B55alpha and Eya3 interaction that can be disrupted by a peptide inhibitor.
    J Biol Chem. 2025;301:110287.
    PubMed         Abstract available
    
    
62. HAN AL, Vinod Paul K, Rao S, Brechbuhl HM, et al
    Estradiol (E2) concentration shapes the chromatin binding landscape of estrogen receptor alpha.
    J Biol Chem. 2025;301:108499.
    PubMed         Abstract available
    
    

    
    J Clin Invest

63. DEVARAJAN R, Izzi V, Peltoketo H, Rask G, et al
    Corrigendum to Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
    J Clin Invest. 2025;135:e196478.
    PubMed        
    
    

    
    J Clin Oncol

64. DILAWARI A, Zhang H, Shah M, Gao X, et al
    US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Recep
    J Clin Oncol. 2025 Aug 5:JCO2500812. doi: 10.1200/JCO-25-00812.
    PubMed         Abstract available
    
    

    
    J Nucl Med

65. ENKE JS, Schuller BW, Glantschnig L, Kircher M, et al
    Biodistribution and Radiation Dosimetry for [(68)Ga]Ga-LNTH-1363S, a Probe Targeting Fibroblast Activation Protein alpha.
    J Nucl Med. 2025;66:1284-1290.
    PubMed         Abstract available
    
    

    
    Lancet

66. LINN SC, Hilbers FS
    Balancing quality and quantity of life in older patients with breast cancer.
    Lancet. 2025;406:422-424.
    PubMed        
    
    
67. BRAIN E, Mir O, Bourbouloux E, Rigal O, et al
    Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
    Lancet. 2025;406:489-500.
    PubMed         Abstract available
    
    

    
    N Engl J Med

68. MCDONNELL DP
    Degradation of the Estrogen Receptor in Breast Cancer.
    N Engl J Med. 2025;393:604-608.
    PubMed        
    
    

    
    Nature

69. HOOVER G, Gilbert S, Curley O, Obellianne C, et al
    Nerve-to-cancer transfer of mitochondria during cancer metastasis.
    Nature. 2025;644:252-262.
    PubMed         Abstract available
    
    

    
    NPJ Breast Cancer

70. GALLUZZI L, Bolini L, Shulman RM
    Radiation therapy as a biological modifier of the breast cancer immune microenvironment.
    NPJ Breast Cancer. 2025;11:84.
    PubMed         Abstract available
    
    
71. BARNARD ME, Qin B, Emerson MA, Holder EX, et al
    Associations between social drivers of health and breast cancer stage at diagnosis among U.S. Black women.
    NPJ Breast Cancer. 2025;11:85.
    PubMed         Abstract available
    
    
72. KLOCKER EV, Dobric N, Graf R, Beichler C, et al
    Clinical impact of single-gene vs. panel sequencing in advanced HR + /HER2- breast cancer: insights and implications.
    NPJ Breast Cancer. 2025;11:86.
    PubMed         Abstract available
    
    

    
    Oncology

73. BASTA A, Lien K, Sun W, Whiting J, et al
    A real-world single-center cohort study on the tolerability of trastuzumab deruxtecan for HER2+ metastatic breast cancer.
    Oncology. 2025 Aug 4:1-18. doi: 10.1159/000547685.
    PubMed         Abstract available
    
    

    
    PLoS One

74. DANIELS J, Kyei KA, Walubo R, Nyantakyi AY, et al
    Prevalence and clinicopathological characteristics of breast cancer patients with brain metastases in Ghana: A single-center cross-sectional study.
    PLoS One. 2025;20:e0329308.
    PubMed         Abstract available
    
    
75. HELU A, Samawi H
    Assessing uncertainty: A study of entropy measures for Burr XII distribution under progressive Type-II censoring.
    PLoS One. 2025;20:e0329086.
    PubMed         Abstract available
    
    
76. AGIDE FD, Garmaroudi G, Sadeghi R, Shakibazadeh E, et al
    Designing and evaluation of the effect of community-based intervention on breast self-examination among reproductive-aged women in Ethiopia: A Cluster Randomized Controlled Trial.
    PLoS One. 2025;20:e0329839.
    PubMed         Abstract available
    
    
77. LU X, Wei C, Li C, Liu J, et al
    Do skin bacteriostatic agents reduce acute radiodermatitis in breast cancer patients? A prospective interventional study.
    PLoS One. 2025;20:e0328536.
    PubMed         Abstract available
    
    
78. TSAI MH, Vo JB, Moore JX, Ramin C, et al
    Mediating effects of mental and physical health on the association between chronic disease conditions and colorectal cancer screening utilization among breast cancer survivors.
    PLoS One. 2025;20:e0328353.
    PubMed         Abstract available
    
    
79. YANG C, Liu Y, Gai L, Zhang Z, et al
    Artesunate regulates malignant progression of breast cancer cells via lncRNA TUG1/miR-145-5p/HOXA5 axis.
    PLoS One. 2025;20:e0329490.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

80. VUILLE JA, Tanriover C, Antmen E, Micalizzi DS, et al
    The E3 ligase HECTD4 regulates COX-2-dependent tumor progression and metastasis.
    Proc Natl Acad Sci U S A. 2025;122:e2425621122.
    PubMed         Abstract available
    
    

    
    Radiol Artif Intell

81. MOASSEFI M, Xiao L
    Sections Don't Lie: AI-driven Breast Cancer Detection Using MRI.
    Radiol Artif Intell. 2025;7:e250520.
    PubMed        
    
    

    
    Radiology

82. METSER U, Ali Mirshahvalad S, Dayes IS, Parpia S, et al
    (18)F-FDG PET/CT of Oligometastatic Disease in Locally Advanced Breast Cancer: PETABC Trial Post Hoc Analysis.
    Radiology. 2025;316:e243788.
    PubMed         Abstract available
    
    
83. YEH R, D'Andrea G
    In Vivo Imaging for Assessing Receptor Status in Breast Cancer.
    Radiology. 2025;316:e243832.
    PubMed        
    
    
84. ULANER GA
    Detection of Oligometastatic Disease in Breast Cancer: It's the Little Things That Count.
    Radiology. 2025;316:e251797.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.